Ute Dugan, MD, PhD, is Chief Medical Officer at the Parker Institute for Cancer Immunotherapy (PICI). She leads clinical and translational research efforts to overcome immunotherapy resistance and advance novel breakthrough treatment combinations.

2021年2月16日 · SAN FRANCISCO – The Parker Institute for Cancer Immunotherapy (PICI) announced today the appointment of Ute Dugan, MD, PhD, as Senior Vice President, Clinical Research. In her new role, Dugan oversees PICI’s clinical development, regulatory affairs and translational medicine efforts, with a focus on overcoming immunotherapy resistance and ...

2022年8月25日 · Ute Dugan, MD, PhD, is Chief Medical Officer at the Parker Institute for Cancer Immunotherapy (PICI). She leads clinical and translational research efforts to overcome immunotherapy resistance and advance novel breakthrough treatment combinations.

2021年4月1日 · Research Institutions. Our academic collaborators’ seminal contributions push the field forward. Directory. Our constellation of renowned thinkers and partners

2021年3月20日 · Mission & Vision. Develop breakthrough immune therapies to turn all cancers into curable diseases faster. Leadership & Staff. The driving force behind PICI’s research and operations

Ute Dugan's 14 research works with 212 citations and 1,556 reads, including: Optimizing Chemotherapy Dose and Schedule by Norton-Simon Mathematical Modeling

2021年2月19日 · Ute Dugan was named senior vice president of clinical research at the Parker Institute for Cancer Immunotherapy.